Awakn Announces First Patient Screened In Phase 3 Clinical Trial Of Awkn 001 For Severe Alcohol Use Disorder

Awakn Life Sciences Announces First Patient Screened in Phase 3 Clinical Trial for Severe Alcohol Use Disorder

Awakn's AWKN-001 Shows Promise in Treating Alcohol Use Disorder

Awakn's Phase 3 Clinical Trial Aims to Further Demonstrate the Efficacy and Safety of AWKN-001

WEB Toronto Canada August 9 2024 - Awakn Life Sciences Corp 954 Awakn or the Company a clinical.

WEB Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder Newsfile Corp. Announced an important milestone on August 9 2024 reporting that the first patient has been screened for its Phase 3 clinical trial. Awakn a clinical-stage biotechnology company announces that the first patient has been screened in the landmark MORE. FSE954 has announced that the first patient has been screened in its..